Known targets — ChEMBL curated mechanism
ACHEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3APH1AAPH1BCHRM2CHRM3EZH2GRIN2AHTR1AHTR1BHTR1DHTR1FHTR3ANCSTNP2RY12PSEN1PSEN2PSENENSIGMAR1SLC6A2SLC6A3SLC6A4
The experimentally established mechanism targets of P-Xylene. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.53 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 2/20 | 0.40 |
| ▸ | RAB9A | P51151 | 4/20 | 0.39 |
| ▸ | NPC1 | O15118 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.38 |
| ▸ | RELA | Q04206 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| P-Xylene SCHEMBL10614849 | 1.00 | TDP1 (0.53) | TDP1TSHRNAPRTACHELMNA | |
| P-Xylene SCHEMBL20640077 | 0.97 | TDP1 (0.50) | TDP1TSHRNAPRTACHELMNA | |
| P-Xylene SCHEMBL1700858 | 0.97 | TDP1 (0.56) | TDP1TSHRNAPRTACHELMNA | |
| P-Xylene SCHEMBL27431590 | 0.97 | TDP1 (0.56) | TDP1TSHRNAPRTACHELMNA | |
| P-Xylene SCHEMBL29229140 | 0.94 | TDP1 (0.53) | TDP1TSHRNAPRTACHELMNA | |
| Toluene SCHEMBL434901 | 0.88 | ACHE (0.65) | TDP1TSHRNAPRTACHELMNA | |
| Pyridine SCHEMBL5590769 | 0.88 | TSHR (0.53) | TDP1TSHRNAPRTACHELMNA | |
| Toluene SCHEMBL27945578 | 0.86 | ACHE (0.61) | TDP1TSHRNAPRTACHELMNA | |
| Toluene SCHEMBL27304983 | 0.86 | ACHE (0.61) | TDP1TSHRNAPRTACHELMNA | |
| SCHEMBL19443810 | 0.86 | TSHR (0.61) | TDP1TSHRNAPRTACHELMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 325 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4745152-A2 | PEPTIDES BINDING TO BFL-1 | Dana-Farber Cancer Institute, Inc. (US) | 2026-05-20 | — | — | EP | disclosed |
| EP-3341008-B1 | PEPTIDES BINDING TO BFL-1 | DANA FARBER CANCER INST INC (US) | 2026-04-15 | — | — | EP | disclosed |
| US-12570698-B2 | Stabilized peptides for covalent binding to target protein | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-03-10 | — | — | US | disclosed |
| US-12528846-B2 | BH4 stabilized peptides and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2026-01-20 | — | — | US | disclosed |
| US-20250326794-A1 | ANTI-CANCER LEUCINE-RICH PEPTIDES AND USES THEREOF | KING'S COLLEGE LONDON (GB) | 2025-10-23 | — | — | US | disclosed |
| EP-4426749-A1 | NOVEL BACTERIAL TRANSLOCATION DOMAINS AND RECOMBINANT POLYPEPTIDES COMPRISING THEM FOR USE IN CELLULAR DELIVERY | The Hospital For Sick Children (CA) | 2024-09-11 | — | — | EP | disclosed |
| US-20240294574-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | DANA-FARBER CANCER INSTITUTE, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20240101733-A1 | MONOGLYCEROL ACRYLATE BASED POLYMER AND USES THEREOF | UNIVERSITé LAVAL (CA) | 2024-03-28 | — | — | US | disclosed |
| US-20240043389-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | ALBERT EINSTEIN COLLEGE OF MEDICINE (US) | 2024-02-08 | — | — | US | disclosed |
| EP-3305320-B1 | ALUMINUM-CONTAINING ADJUVANT COMPOSITION, AND VACCINE COMPOSITION CONTAINING SAME | TERUMO CORP (JP) | 2024-02-07 | — | — | EP | disclosed |
| US-5296231-A | Producing liposome encapsulated DNA repair enzyme | APPLIED GENETICS, INC. (US) | 1994-03-22 | — | — | US | disclosed |
| US-5272079-A | Purification and administration of DNA repair enzymes | APPLIED GENETICS, INC. (US) | 1993-12-21 | — | — | US | disclosed |
| US-5190762-A | DNA repair enzymes encapsulated in liposomes | APPLIED GENETICS, INC. (US) | 1993-03-02 | — | — | US | disclosed |
| EP-0423214-A4 | PURIFICATION AND ADMINISTRATION OF DNA REPAIR ENZYMES | — | 1991-11-13 | — | — | EP | disclosed |
| EP-0423214-A1 | PURIFICATION AND ADMINISTRATION OF DNA REPAIR ENZYMES. | APPLIED GENETICS INC (US) | 1991-04-24 | — | — | EP | disclosed |
| WO-1990000598-A1 | PURIFICATION AND ADMINISTRATION OF DNA REPAIR ENZYMES | APPLIED GENETICS, INC. (US) | 1990-01-25 | — | — | WO | disclosed |
| EP-0185738-A4 | IMMUNOLIPOSOME ASSAY - METHODS AND PRODUCTS. | UNIV TENNESSEE RES CORP (US) | 1988-07-14 | — | — | EP | disclosed |
| US-4708933-A | Immunoliposome assay-methods and products | BIOWHITTAKER, INC. A CORP. OF DELAWARE | 1987-11-24 | — | — | US | disclosed |
| EP-0185738-A1 | IMMUNOLIPOSOME ASSAY - METHODS AND PRODUCTS | THE UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1986-07-02 | — | — | EP | disclosed |
| WO-1986000142-A1 | IMMUNOLIPOSOME ASSAY - METHODS AND PRODUCTS | UNIVERSITY OF TENNESSEE RESEARCH CORPORATION (US) | 1986-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12528846-B2 | BH4 stabilized peptides and uses thereof | BCL2, BCL2L13, BAX | ACHE 4588/4885TDP1 1436/4885TSHR 3123/4885 |
| US-20240294574-A1 | STABILIZED PEPTIDES FOR COVALENT BINDING TO TARGET PROTEIN | HSPBP1, HSPA8, PTMS | ACHE 4496/4885TDP1 3688/4885TSHR 2652/4885 |
| US-12570698-B2 | Stabilized peptides for covalent binding to target protein | STUB1, JMJD7, PTMS | ACHE 3102/4885TDP1 3504/4885TSHR 1652/4885 |
| US-20240043389-A1 | COMPOUNDS AND METHODS FOR INHIBITION OF BAX-MEDIATED CELL DEATH | BAX, BCL2, BAD | ACHE 3944/4885TDP1 801/4885TSHR 4816/4885 |
| US-20240101733-A1 | MONOGLYCEROL ACRYLATE BASED POLYMER AND USES THEREOF | PLA2G2A, PHOSPHO1, PLA2G4A | ACHE 4017/4885TDP1 3342/4885TSHR 3708/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.